Table 2.
Studies including lymphomatoid papulosis (LYP) patients treated with radiation therapy (RT).
| Author [ref.] | Study type | Number of LYP patients treated with RT | Number of LYP lesions treated | Associated lymphoma | Locations of treated lesion | TNM stage at presentation∗ | Other treatments | RT details | CR rate | LR | Time to LR (m) | Follow-up (m) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thomsen and Schmidt [21] | E | 1 | 1 | MF | n/s | T3bN0 | Topical 5-FU, topical steroids, PUVA | Localized RT | 100% | Y | n/s | |
|
| ||||||||||||
| Willemze et al. [15] | R | 1 | 2 | LCL | n/s | TSEBR, 40 Gy, 4 MeV | 100% | Y | 3 | |||
| n/s | Localized RT, 25 Gy, 100 kV | 100% | Y | 5 | ||||||||
|
| ||||||||||||
| Sanchez et al. [16] | R | 4 | MF | n/s | T3aN0 | Topical corticosteroids, photochemotherapy, chlorambucil, prednisone, combination chemotherapy | TSEBR, 30 Gy, 6 MeV e− | 0% | N | |||
| MF | n/s | T3aN0 | Topical nitrogen mustard | Localized RT | 0% | N | ||||||
| HL | n/s | Mustine HCL, vincristine, sulfate, prednisone, procarbazine HCL | 100% | Y | n/s | |||||||
| ML | n/s | Localized RT | 0% | N | ||||||||
|
| ||||||||||||
|
Sina and Burnett [22] |
R | 2 | 2 | Left thigh | T3bN0 | Localized RT, 6/2 Gy, 15 kV, 30 mm HVL | 100% | N | 14 | |||
| n/s | T3bN0 | Localized RT | 100% | N | 36 | |||||||
|
| ||||||||||||
|
Kaufmann et al. [19] |
R | 1 | 2 | Right forearm | T1bN0 | Localized RT, 35/2–2.5 Gy, 6 MeV e−, 0.5 cm bolus, 90% IDL | 100% | N | ||||
| Right finger | Localized RT, 30/2 Gy, 6 MeV e− | 100% | N | |||||||||
|
| ||||||||||||
| Wilson et al. [18] | R | 3 | n/s | T1-3Nx | Topical steroids, PUVA, topical nitrogen mustard | TSEBR/6 fields, 36/1 Gy, 6 MeV e−, supplemented 20/1 Gy, 120 kV to perineum, soles of feet and 6/2 Gy, 120 kV to apical scalp | 100% | Y | 4.8; 3-year DFS 20% | 44.1 (median) | ||
|
| ||||||||||||
| J. Breneman and D. Breneman [17] |
E | 5 | MF | n/s | n/s; 1 patient received concurrent CHOP | TSEBR/modified Stanford, 36 Gy | 80% | N | 12, 48, 61, and 70 | |||
|
| ||||||||||||
| Christensen et al. [24] | R | 6 | 6 | n/s | Localized RT | 100% | N | |||||
|
| ||||||||||||
| Cabanillas et al. [3] | R | 4 | CTCL/MF/ LCL | n/s | 0% | Y | n/s | |||||
|
| ||||||||||||
|
Kaufmann et al. [20] |
R | 1 | 4 | Right forearm, left forearm ×3 | T1bN0 | Localized RT, 30/2 Gy, 6 MeV e−, 0.5 cm bolus daily | 100% | N | 45 | |||
|
| ||||||||||||
| Scarisbrick et al. [23] | R | 2 | 2 | Left flank | T2aN0 | Localized RT, 8/2 Gy, 100 kV | 0% (100% with retreatment) | Y | 6 | 12 | ||
| Lower abdomen | T2aN0 | Localized RT, 8/2 Gy, 100 kV | 100% | N | 12 | |||||||
∗Retrospective staging according to Kim et al., 2007 [25].
E = editorial, R = retrospective, MF = mycosis fungoides, LCL = large-cell lymphoma, HL = Hodgkin's Lymphoma, ML = malignant lymphoma NOS, CTCL = cutaneous T-cell lymphoma, PUVA = psoralen and ultraviolet A therapy, n/a = not applicable, n/s = not specified, TSEBR = total skin electron beam radiotherapy, e− = electron, HVL = half value layer, LR = local recurrence, and DFS = disease-free survival.